← All trials
NCT03370874
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 4, 2018
- Primary completion
- Jun 30, 2019
- Completion date
- Sep 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 164
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Anterogen Co., Ltd.Lead sponsor
- Korea UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Eulji UniversityOverall official - principal investigator
- Chungnam National UniversityOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Konkuk UniversityOverall official - principal investigator
- Ajou UniversityOverall official - principal investigator
- Keimyung UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.